HMGB3 and non-small cell lung carcinoma: Inhibition of HMGB3 expression leads to decreased viability, proliferation, migration, and invasion of cells in breast cancer [121], cervical cancer [204], esophageal cancer [205], non-small-cell lung cancer (NSCLC) [206,207,208], and stomach cancer [177].